# Hans Kupper

> Hans Kupper is a Series A investor at Global Life Science Ventures backing Health Care. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Global Life Science Ventures](https://shizune.co/investors/profile/global-life-science-ventures)
- Location: München, Germany
- Total investments: 3
- Last investment: Jul 2010
- Lead investor: 33%
- Last updated: Aug 2026

Hans Kupper is a Series A investor at Global Life Science Ventures in München focused on Health Care and Biotechnology. Dr. Hans Kupper is a partner at Global Life Science Ventures since 1999. Dr Kupper has 29 years of experience in biotechnology with 19 years in the life science industry, where he has been involved in activities from R&D and R&D management to technology assessment and acquisitions.In 1980, Dr. Kupper joined Biogen where he held variousR&D and management positions, including Assistant Research Director.In 1985, he joined Behringwerke AG to build and head the Molecular Biology Department and later became head of R&D at the Immunology/Oncology business unit.Since 1991, Dr Kupper has been increasingly involved in deal negotiations, acquisitions, joint ventures, and lead the spin-off of the vaccine unit and the diagnostics business of Behringwerke AG.Dr Kupper earned a PhD from the University of Heidelberg and was a postdoctoral fellow at MIT in Boston with Nobel Laureate Prof. Khorana.Dr. Kupper is a member on several Boards of Directors including Chairman of the Board of Pieris, board member of Action Pharma, IMI Intelligent Medical Implants, and an observer of the board of 7TM.Dr. Kupper was first elected to the Board of Santaris Pharma A/S in 2010.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 67% |
| Biotechnology | 2 | 67% |
| Pharmaceutical | 2 | 67% |
| Medical | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Series B | 1 | 33% |
| Series C | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Denmark | 1 | 33% |
| Germany | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Action Pharma | Action Pharma A/S operates as a research and development focused biotechnology company. It discovers and develops new drugs and treatment concepts to treat cardiovascular disease and inflammatory diseases, as well as metabolic diseases, such as type-II diabetes and obesity. The company's product pipeline includes AP214, a modifiedÐMSH-peptide analogue for the treatment of post-surgical kidney injury associated with cardiac surgery; and AP1030 and AP11 series, oral anti-diabetic (OAD) for the treatment of type-II diabetes associated with overweight/obesity. Its product pipeline also comprise AP1189, an oral anti-inflammatory compound for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and AP405, a modified MSH peptide analogue for the treatment of inflammatory skin diseases, such as atopic dermatitis. The company was founded in 2000 and is based in Holte, Denmark. | $6.3M | Series C | Jul 16, 2010 |  |
| Pieris | Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and other medical conditions with unmet medical needs. The company applies its proprietary Anticalin® technology to the drug development processes. Pieris Pharmaceuticals was founded in 2001 and is based in Freising,Bayern. | $6.4M | Series B | Nov 01, 2006 |  |
| Pieris | Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and other medical conditions with unmet medical needs. The company applies its proprietary Anticalin® technology to the drug development processes. Pieris Pharmaceuticals was founded in 2001 and is based in Freising,Bayern. | $13.2M | Series A | Oct 31, 2002 |  |

3 of 3 investments shown.

## Co-investors
- [AAC Capital Partners](https://shizune.co/investors/profile/aac-capital-partners) — VC Fund, 1 deal together
- [ABN AMRO Fund](https://shizune.co/investors/profile/abn-amro) — VC Fund, 1 deal together
- [BayTech Venture Capital](https://shizune.co/investors/profile/baytech-venture-capital) — VC Fund, 1 deal together
- [BioM AG](https://shizune.co/investors/profile/biom-ag) — VC Fund, 1 deal together
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 1 deal together
- [Gilde Healthcare](https://shizune.co/investors/profile/gilde-healthcare-partners) — VC Fund, 1 deal together

## About Global Life Science Ventures

VC Fund · München, Germany

Global Life Science Ventures (GLSV) was a venture capital fund focusing exclusively on the life sciences. GLSV was dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund also invested in selected later stage companies, including buy-outs. For this purpose, GLSV provided finance,advice and access to expertise and networks. The group advised and managed funds totaling more than € 200 million. With offices in Germany and Switzerland, GLSV acted as one team with a global perspective. The first fund started its activities in 1996 and invested in 18 companies. The second fund GLSV II started in 2001 and invested in 18 companies primarily in Europe and the US. After termination of the investment period, the fund exited the remaining assets in 2015 and is in liquidation.

3 contacts available at Global Life Science Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Hans Kupper | Partner | https://shizune.co/investors/profile/hans-kupper |
| Bert van Toor | Investment Manager | https://shizune.co/investors/profile/bert-van-toor |
| Peter Reinisch | Partner | https://shizune.co/investors/profile/peter-h-reinisch |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Hans Kupper invest in?

Hans Kupper invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Hans Kupper last invest?

The most recent investment recorded for Hans Kupper closed in Jul 2010. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co